Differentiation-dependent doxorubicin toxicity on h9c2 cardiomyoblasts

Cardiovascular Toxicology

Volumn 12, Issue 4, 2012, Pages 326-340

  Branco, Ana F ^a   Sampaio, Susana F ^a   Moreira, Ana C ^a   Holy, Jon ^b   Wallace, Kendall B ^b   Baldeiras, Ines ^a,c   Oliveira, Paulo J ^a   Sardão, Vilma A ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cardiac toxicity; Doxorubicin; Heart; Myoblasts

Indexed keywords

DOXORUBICIN; PROTEIN BCL XL; PROTEIN P53; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CARDIOMYOBLAST; CARDIOTOXICITY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL POPULATION; CELL STIMULATION; CELL STRESS; CONTROLLED STUDY; CYTOTOXICITY; DEVELOPMENTAL STAGE; EMBRYO CELL; HEART MUSCLE CELL; MYOBLAST; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE;

ANIMALS; CARDIOTOXINS; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; DOXORUBICIN; MYOBLASTS, CARDIAC; MYOCYTES, CARDIAC; RATS;

RATTUS;

EID: 84870546889     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-012-9177-8     Document Type: Article

References (58)

1. Fulbright, J. M., Huh, W., Anderson, P., & Chandra, J. (2010). Can anthracycline therapy for pediatric malignancies be less cardiotoxic Current Oncology Reports, 12, 411-419.
2. Lipshultz, S. E. (2006). Exposure to anthracyclines during childhood causes cardiac injury. Seminars in Oncology, 33, S8-14.
3. van der Pal, H. J., van Dalen, E. C., Hauptmann, M., Kok, W. E., Caron, H. N., van den Bos, C., et al. (2010). Cardiac function in 5-year survivors of childhood cancer: A long-term follow-up study. Archives of Internal Medicine, 170, 1247-1255.
4. Broder, H., Gottlieb, R. A., & Lepor, N. E. (2008). Chemotherapy and cardiotoxicity. Reviews in Cardiovascular Medicine, 9, 75-83.
5. Lefrak, E. A., Pitha, J., Rosenheim, S., & Gottlieb, J. A. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32, 302-314.
6. Steinherz, L., & Steinherz, P. (1991). Delayed cardiac toxicity from anthracycline therapy. Pediatrician, 18, 49-52.
7. Huang, C., Zhang, X., Ramil, J. M., Rikka, S., Kim, L., Lee, Y., et al. (2010). Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation, 121, 675-683.
8. De Angelis, A., Piegari, E., Cappetta, D., Marino, L., Filippelli, A., Berrino, L., et al. (2009). Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation, 121, 276-292.
9. Konorev, E. A., Vanamala, S., & Kalyanaraman, B. (2008). Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes. Free Radical Biology and Medicine, 45, 1723-1728.
10. Azim, H. A., Jr, Peccatori, F. A., Scarfone, G., Acaia, B., Rossi, P., Cascio, R., et al. (2008). Anthracyclines for gestational breast cancer: Course and outcome of pregnancy. Annals of Oncology, 19, 1511-1512.
11. Lam, M. S. (2006). Treatment of Burkitt's lymphoma during pregnancy. Annals of Pharmacotherapy, 40, 2048-2052.
12. Kerr, J. R. (2005). Neonatal effects of breast cancer chemotherapy administered during pregnancy. Pharmacotherapy, 25, 438-441.
13. Van Calsteren, K., Verbesselt, R., Beijnen, J., Devlieger, R., De Catte, L., Chai, D. C., et al. (2010). Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecologic Oncology, 119, 594-600.
14. Kimes, B. W., & Brandt, B. L. (1976). Properties of a clonal muscle cell line from rat heart. Experimental Cell Research, 98, 367-381.
15. Hescheler, J., Meyer, R., Plant, S., Krautwurst, D., Rosenthal, W., & Schultz, G. (1991). Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circulation Research, 69, 1476-1486.
16. Menard, C., Pupier, S., Mornet, D., Kitzmann, M., Nargeot, J., & Lory, P. (1999). Modulation of L-type calcium channel expression during retinoic acid-induced differentiation of H9C2 cardiac cells. Journal of Biological Chemistry, 274, 29063-29070.
17. Zhu, H. L., Wei, X., Qu, S. L., Zhang, C., Zuo, X. X., Feng, Y. S., et al. (2011). Ischemic postconditioning protects cardiomyocytes against ischemia/reperfusion injury by inducing MIP2. Experimental & Molecular Medicine, 43, 437-445.
18. Yu, X. Y., Chen, H. M., Liang, J. L., Lin, Q. X., Tan, H. H., Fu, Y. H., et al. (2011). Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: Macrophage migration inhibitory factor. PLoS One, 6, e16239.
19. Gurusamy, N., Lekli, I., Mukherjee, S., Ray, D., Ahsan, M. K., Gherghiceanu, M., et al. (2009). Cardioprotection by resveratrol: A novel mechanism via autophagy involving the mTORC2 pathway. Cardiovascular Research, 86, 103-112.
20. Silva, J. P., Sardao, V. A., Coutinho, O. P., & Oliveira, P. J. (2010). Nitrogen compounds prevent h9c2 myoblast oxidative stress-induced mitochondrial dysfunction and cell death. Cardiovascular Toxicology, 10, 51-65.
21. Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2007). Vital imaging of H9c2 myoblasts exposed to tertbutylhydroperoxide-characterization of morphological features of cell death. BMC Cell Biol, 8, 11.
22. Sipkens, J. A., Krijnen, P. A., Hahn, N. E., Wassink, M., Meischl, C., Smith, D. E., et al. (2011). Homocysteine-induced cardiomyocyte apoptosis and plasma membrane flip-flop are independent of S-adenosylhomocysteine: A crucial role for nuclear p47(phox). Molecular and Cellular Biochemistry, 358, 229-239.
23. Lund, K. C., Peterson, L. L.,&Wallace, K. B. (2007). Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrobial Agents and Chemotherapy, 51, 2531-2539.
24. Comelli, M., Metelli, G., & Mavelli, I. (2007). Downmodulation of mitochondrial F0F1 ATP synthase by diazoxide in cardiac myoblasts: A dual effect of the drug. American Journal of Physiology. Heart and Circulatory Physiology, 292, H820-829.
25. Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2011). Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death & Disease, 2, e190.
26. L'Ecuyer, T. J., Aggarwal, S., Zhang, J. P., & Van der Heide, R. S. (2011). Effect of hypothermia on doxorubicin-induced cardiac myoblast signaling and cell death. Cardiovascular Pathology, 21, 96-104.
27. Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2009). Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biology and Toxicology, 25, 227-243.
28. Sardao, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemotherapy and Pharmacology, 64, 811-827.
29. Pereira, S. L., Ramalho-Santos, J., Branco, A. F., Sardao, V. A., Oliveira, P. J., & Carvalho, R. A. (2011). Metabolic remodeling during H9c2 myoblast differentiation: Relevance for in vitro toxicity studies. Cardiovascular Toxicology, 11, 180-190.
30. Branco, A. F., Pereira, S. L., Moreira, A. C., Holy, J., Sardao, V. A., & Oliveira, P. J. (2011). Isoproterenol cytotoxicity is dependent on the differentiation state of the cardiomyoblast H9c2 cell line. Cardiovascular Toxicology, 11, 191-203.
31. Holy, J., Kolomitsyna, O., Krasutsky, D., Oliveira, P. J., Perkins, E., & Krasutsky, P. A. (2010). Dimethylaminopyridine derivativesof lupane triterpenoids are potent disruptors of mitochondrial structure and function. Bioorganic & Medicinal Chemistry, 18, 6080-6088.
32. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
33. Pastore, A., Federici, G., Bertini, E., & Piemonte, F. (2003). Analysis of glutathione: implication in redox and detoxification. Clinical Chimical Acta, 333, 19-39.
34. Umemoto, T., Furutani, Y., Murakami, M., Matsui, T., & Funaba, M. (2011). Endogenous Bmp4 in myoblasts is required for myotube formation in C2C12 cells. Biochimica et Biophysica Acta, 1810, 1127-1135.
35. Doroshow, J. H., & Davies, K. J. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. Journal of Biological Chemistry, 261, 3068-3074.
36. Chinopoulos, C., & Adam-Vizi, V. (2011). Modulation of the mitochondrial permeability transition by cyclophilin D: Moving closer to F(0)-F(1) ATP synthase Mitochondrion, 12, 41-45.
37. Hom, J. R., Quintanilla, R. A., Hoffman, D. L., de Mesy Bentley, K. L., Molkentin, J. D., Sheu, S. S., et al. (2011). The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Developmental Cell, 21, 469-478.
38. Soriano, M. E., & Scorrano, L. (2011). Traveling Bax and forth from mitochondria to control apoptosis. Cell, 145, 15-17.
39. Chen, Y. B., Aon, M. A., Hsu, Y. T., Soane, L., Teng, X., McCaffery, J. M., et al. (2011). Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential. Journal of Cell Biology, 195, 263-276.
40. Velez, J. M., Miriyala, S., Nithipongvanitch, R., Noel, T., Plabplueng, C. D., Oberley, T., et al. (2011). p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One, 6, e18005.
41. Feridooni, T., Hotchkiss, A., Remley-Carr, S., Saga, Y., & Pasumarthi, K. B. (2011). Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One, 6, e22801.
42. Oliveira, P. J., & Wallace, K. B. (2006). Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats-relevance for mitochondrial dysfunction. Toxicology, 220, 160-168.
43. Zhou, S., Starkov, A., Froberg, M. K., Leino, R. L., & Wallace, K. B. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Research, 61, 771-777.
44. Davis, L. E., & Brown, C. E. (1988). Peripartum heart failure in a patient treated previously with doxorubicin. Obstetrics & Gynecology, 71, 506-508.
45. Katz, A., Goldenberg, I., Maoz, C., Thaler, M., Grossman, E., & Rosenthal, T. (1997). Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin. American Journal of the Medical Sciences, 314, 399-400.
46. Oliveira, P. J., Bjork, J. A., Santos, M. S., Leino, R. L., Froberg, M. K., Moreno, A. J., et al. (2004). Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicology and Applied Pharmacology, 200, 159-168.
47. Oliveira, P. J., Santos, M. S., & Wallace, K. B. (2006). Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry (Moscow), 71, 194-199.
48. Pereira, G. C., Silva, A. M., Diogo, C. V., Carvalho, F. S., Monteiro, P., & Oliveiraalo, P. J. (2011). Drug-induced cardiac mitochondrial toxicity and protection: From doxorubicin to carvedilol. Current Pharmaceutical Design, 17, 2113-2129.
49. Berthiaume, J. M., & Wallace, K. B. (2007). Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment. Cardiovascular Toxicology, 7, 178-191.
50. Schopf, G., Rumpold, H., & Muller, M. M. (1986). Alterations of purine salvage pathways during differentiation of rat heart myoblasts towards myocytes. Biochimica et Biophysica Acta, 884, 319-325.
51. Hammes, A., Oberdorf, S., Strehler, E. E., Stauffer, T., Carafoli, E., Vetter, H., et al. (1994). Differentiation-specific isoform mRNA expression of the calmodulin-dependent plasma membrane Ca(2)-ATPase. FASEB Journal, 8, 428-435.
52. Hunter, A. L., Zhang, J., Chen, S. C., Si, X., Wong, B., Ekhterae, D., et al. (2007). Apoptosis repressor with caspase recruitment domain (ARC) inhibits myogenic differentiation. FEBS Letter, 581, 879-884.
53. Bregant, E., Renzone, G., Lonigro, R., Passon, N., Di Loreto, C., Pandolfi, M., et al. (2009). Down-regulation of SM22/transgelin gene expression during H9c2 cells differentiation. Molecular and Cellular Biochemistry, 327, 145-152.
54. Muller, C., Chatelut, E., Gualano, V., De Forni, M., Huguet, F., Attal, M., et al. (1993). Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: Comparison of bolus administration and continuous infusion. Cancer Chemotherapy and Pharmacology, 32, 379-384.
55. Greene, R. F., Collins, J. M., Jenkins, J. F., Speyer, J. L., & Myers, C. E. (1983). Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Research, 43, 3417-3421.
56. Cutts, S. M., Nudelman, A., Rephaeli, A., & Phillips, D. R. (2005). The power and potential of doxorubicin-DNA adducts. IUBMB Life, 57, 73-81.
57. Sharaf el dein, O., Mayola, E., Chopineau, J., & Brenner, C. (2011). The adenine nucleotide translocase 2, a mitochondrial target for anticancer biotherapy. Current Drug Targets, 12, 894-901.
58. Govoni, M., Bonavita, F., Shantz, L. M., Guarnieri, C., & Giordano, E. (2010). Overexpression of ornithine decarboxylase increases myogenic potential of H9c2 rat myoblasts. Amino Acids, 38, 541-547.